ANDA 218031, held by Novast Labs. Drospirenone; Estradiol.
As of Nov 16, 2026, ANDA 218031 (Drospirenone And Estradiol), held by Novast Labs, was first approved by FDA on Oct 28, 2025, with 1 approved supplement and 0 published complete response letters.
| Oct 28, 2025 | Original application | Approved | None posted |
| Oct 28, 2025 | Original application | Tentative approval |
| Product | Active ingredient | Marketing |
|---|---|---|
| Drospirenone And Estradiol0.5MG;1MG · tablet;oral | Drospirenone; Estradiol | Rx |
| Oct 26, 2026 | Supplement 2Labeling · Standard review | Approved | None posted |
| Oct 28, 2025 | Original application | Approved | None posted |
| Oct 28, 2025 | Original application | Tentative approval |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters